|Videos|July 22, 2020

Providers: Face Masks Outside Hospital Settings, Counseling Patients on COVID-19

In this second installment of his interview, Howard Koh, MD, MPH, discusses the importance of providers and health care workers wearing face masks during their interactions with patients.

Outside of a hospital setting, providers may want to consider wearing face masks when seeing patients. The population of asymptomatic coronavirus 2019 (COVID-19) patients is much larger than expected. Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases said earlier this week that people with COVID-19 exhibiting no symptoms is somewhere between 20%-40%. This demonstrates that there is so much uncertainty about the way the virus behaves and reinforces that there is so much more to learn.

With such a large percentage of people who are asymptomatic, this could lead to a number of people unknowingly transmitting the virus to others.

With this understanding and a siginificant emphasis on prevention, Howard Koh, MD, MPH, is an advocate for both providers and patients wearing face masks. Koh is the Harvey V. Fineberg Professor of the Practice of Public Health Leadership at the Harvard T.H. Chan School of Public Health and the Kennedy School. Koh also served as the Assistant Secretary for Health for the U.S. Department of Health and Human Services within the Obama administration.

In the second installment of his interview with Contagion®, Koh discusses the importance of providers and health care workers wearing masks during their interactions with patients and having continuous discussions with patients on prevention.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.